CD79A and CD4+/CD56+ hematodermic neoplasm: Garnache-Ottou et al. suggested a scoring system for the diagnosis of BPDCN that requires the investigation of BDCA-2, CD123, and BDCA-4 expression and a limited number of lineage-specific markers (CD4, CD56, CD11c, MPO, cytoplasmic CD79a, and cytoplasmic CD3) [12].